46 min listen
New class of small molecule therapeutics introduced
New class of small molecule therapeutics introduced
ratings:
Length:
27 minutes
Released:
Nov 24, 2023
Format:
Podcast episode
Description
On this week’s podcast we have a conversation with Jordi Mata-Fink, co-founder and chief executive officer of the newly-launched U.S. company Gate Bioscience.00:45-01:06: About Gate Bioscience 01:06-02:09: What are disease-causing extracellular proteins?02:09-04:44: How have diseases caused by extracellular proteins been treated in the past? 04:44-05:47: Have there been diseases that haven’t been addressed? 05:47-07:05: Tackling the different issues created by extracellular proteins 07:05-09:41: What are molecular gates? 09:41-12:56: How does your technique distinguish between good and bad extracellular proteins?12:56-16:24: How did the idea become a company?16:24-17:24: Which diseases will you focus on?17:24-18;47: How do you address costs? 18:47-19:11: How will this be given to patients?19:11-20:01: Disease cure or disease management? 20:01-21:35: How was the company created? 21:35-24:18: The rise of small molecules24:18-25:58: What are the next steps?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter
Released:
Nov 24, 2023
Format:
Podcast episode
Titles in the series (95)
Beyond Biotech podcast 6: Mogrify, +ND Capital, Poolbeg Pharma by Beyond Biotech - the podcast from Labiotech